Zhengfei Zhu, MD
Fudan University
8
8
1
N/A
0
2
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+3 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (8)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Lin Wu
Hunan Cancer Hospital
Shared therapeutic areas:
Worked with same sponsors:
Jiwei Liu
The First Affiliated Hospital of Dalian Medical University
Shared therapeutic areas:
Worked with same sponsors:
Zhenzhou Yang
The Second Affiliated Hospital of Chongqing Medical University
Shared therapeutic areas:
Worked with same sponsors:
Yanyang Wang
General Hospital of Ningxia Medical University
Shared therapeutic areas:
Worked with same sponsors:
Jichen Ren
Jilin Provincial Tumor Hospital
Shared therapeutic areas:
Worked with same sponsors:
Dejun XIng
Jilin Provincial Tumor Hospital
Shared therapeutic areas:
Worked with same sponsors:
Hongqing Zhuang
Peking University Third Hospital
Shared therapeutic areas:
Worked with same sponsors:
Jinjun Ye
Jiangsu Cancer Institute & Hospital
Shared therapeutic areas:
Worked with same sponsors:
Jiancheng Li
Fujian Cancer Hospital
Shared therapeutic areas:
Worked with same sponsors:
Anwen Liu
Second Affiliated Hospital of Nanchang University
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (8)
Showing 8 of 8 trials
SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI
Pamiparib for Consolidation Treatment of Unprogressed LS-SCLC After Concurrent Chemoradiotherapy
SRT for Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs
Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC
SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms
SBRT in Combination With Sintilimab and GM-CSF for the Treatment of Advanced NSCLC
Prospective Observation of Failure Patterns in NSCLC Treated With ICIs
All 8 trials loaded